Codexis, Inc. reiterated earnings guidance for 2022. For the year Total revenues are expected to be in the range of $135 million to $141 million. Product revenues are expected to be in the range of $112 million to $118 million, including approximately $75 million from Pfizer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 USD | -0.63% | -10.26% | +3.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.28% | 222M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Codexis, Inc. Reiterates Earnings Guidance for 2022